SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-23-032540
Filing Date
2023-09-14
Accepted
2023-09-13 21:47:15
Documents
69
Period of Report
2023-06-30

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 1217898
2 ex31-1.htm EX-31.1 12990
3 ex32-1.htm EX-32.1 6765
  Complete submission text file 0001493152-23-032540.txt   6825244

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE ards-20230630.xsd EX-101.SCH 60463
5 XBRL CALCULATION FILE ards-20230630_cal.xml EX-101.CAL 60949
6 XBRL DEFINITION FILE ards-20230630_def.xml EX-101.DEF 274075
7 XBRL LABEL FILE ards-20230630_lab.xml EX-101.LAB 446241
8 XBRL PRESENTATION FILE ards-20230630_pre.xml EX-101.PRE 367432
63 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 1044714
Mailing Address 983 UNIVERSITY AVENUE, BLDG. B LOS GATOS CA 95032
Business Address 983 UNIVERSITY AVENUE, BLDG. B LOS GATOS CA 95032 (408) 385-1742
Aridis Pharmaceuticals, Inc. (Filer) CIK: 0001614067 (see all company filings)

IRS No.: 320074500 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38630 | Film No.: 231253936
SIC: 2834 Pharmaceutical Preparations